Get the Stockscreener App
35.73
4.40%
1.555
Alkermes Plc stock is traded at $35.73, with a volume of 1.70M.
It is up +4.40% in the last 24 hours and up +2.40% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$34.17
Open:
$35.25
24h Volume:
1.70M
Relative Volume:
0.77
Market Cap:
$5.94B
Revenue:
$1.48B
Net Income/Loss:
$241.66M
P/E Ratio:
24.94
EPS:
1.4325
Net Cash Flow:
$480.33M
1W Performance:
+4.50%
1M Performance:
+2.40%
6M Performance:
+14.82%
1Y Performance:
+13.61%
1-Day Range:
$34.07
$35.90
1-Week Range:
$33.12
$35.90
52-Week Range:
$25.16
$36.48
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
35.75 | 5.68B | 1.48B | 241.66M | 480.33M | 1.4325 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.88 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.62 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.23 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
574.99 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Stifel raises Alkermes stock price target on orexin pipeline progress - Investing.com
Alkermes Q1 2026 slides: Avadel deal drives revenue beat - Investing.com
Alkermes plc Reports First Quarter 2026 Financial Results - BioSpace
ALKS: Q1 2026 delivered robust sales growth, expanded sleep medicine presence, and advanced orexin pipeline - TradingView
Earnings call transcript: Alkermes Q1 2026 results beat expectations, stock rises - Investing.com
Alkermes Plc reports results for the quarter ended March 31Earnings Summary - TradingView
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo! Finance Canada
Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss - ChartMill
Alkermes rises as quarterly loss narrows, tops estimates - Investing.com
(ALKS) Alkermes Expects 2026 Revenue Range $1.73B$1.84B, vs. FactSet Est of $1.80B - marketscreener.com
Earnings Flash (ALKS) Alkermes Posts Q1 Net Loss $0.40 a Share, vs. FactSet Est of $0.58 Loss - marketscreener.com
Alkermes reports Q1 2026: Revenues $392.9M, GAAP loss $66.5M, Adjusted EBITDA $80.3M - TradingView
Alkermes: Q1 Earnings Snapshot - KING5.com
Avadel deal drives Alkermes (NASDAQ: ALKS) Q1 growth and 2026 EBITDA upgrade - Stock Titan
Alkermes Q1 2026 earnings preview - MSN
Alkermes earnings on deck: Can Lumryz offset Avadel deal costs? By Investing.com - Investing.com Nigeria
Alkermes earnings on deck: Can Lumryz offset Avadel deal costs? - Investing.com
ALKS SEC FilingsAlkermes Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Avadel Pharmaceuticals 2025 Financial Results, Alkermes Acquisition, and LUMRYZ Commercial Highlights - Minichart
Alkermes (NASDAQ:ALKS) EVP Sells $300,600.00 in Stock - MarketBeat
Alkermes (NASDAQ: ALKS) EVP exercises 5,000 options and sells 9,000 shares - Stock Titan
Alkermes (NASDAQ: ALKS) details Avadel buyout terms and 2025 results - Stock Titan
Alkermes plc (NASDAQ: ALKS) insider sales, option exercise and PSU vesting noted - Stock Titan
Behavioral Patterns of ALKS and Institutional Flows - Stock Traders Daily
Alkermes plc $ALKS Shares Bought by Pictet Asset Management Holding SA - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $5.44 Million Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes (NASDAQ:ALKS) Rating Increased to Hold at Zacks Research - MarketBeat
Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential - ChartMill
Do options traders know something about Alkermes stock we don't? - MSN
Vanguard Portfolio Management (NASDAQ: ALKS) reports 9.65M shares beneficially owned - Stock Titan
Alkermes (ALKS) Expected to Announce Earnings on Tuesday - MarketBeat
Wall Street Analysts Believe Alkermes (ALKS) Could Rally 29.14%: Here's is How to Trade - Zacks Investment Research
Vanguard holds 8.68M shares in Alkermes (NASDAQ: ALKS) via Schedule 13G - Stock Titan
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline - Yahoo Finance
Alkermes plc Announces CEO Succession Plan - Quantisnow
Alkermes announces CEO succession plan - MSN
Are options traders betting on a big move in Alkermes stock? - MSN
Wells Fargo Maintains Alkermes (ALKS) Overweight Recommendation - MSN
Alkermes plc (ALKS) Investor Outlook: Analyzing a 32.80% Upside Potential Amidst a Challenging Year - DirectorsTalk Interviews
Avadel Stock Rises After Acquisition Offer By Alkermes - MSN
Did New Alixorexton Data and LYBALVI Outcomes Just Shift Alkermes' (ALKS) Neuroscience Investment Narrative? - Yahoo Finance
ALKS stock surges 15% on Lilly-Centessa buyout igniting sleep pipeline hopes - MSN
Abacus FCF Advisors LLC Makes New Investment in Alkermes plc $ALKS - MarketBeat
Alkermes plc (NASDAQ:ALKS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Alkermes (NASDAQ:ALKS) Share Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Do Options Traders Know Something About Alkermes Stock We Don't? - TradingView
Alkermes to Report First Quarter Financial Results on May 5, 2026 - 富途牛牛
Is It Too Late To Consider Alkermes (ALKS) After Its Recent 19% Share Price Jump? - simplywall.st
Alkermes (ALKS) nears 52-week high on increasing orexin receptor market interest - MSN
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.26%
3.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):